Table 1.
Baseline Characteristics of Patients and Therapies During the Study (n = 28)
| Baseline | 3 Month | 6 Month | |
|---|---|---|---|
| Age, y | 62.9 ± 9.6 | ||
| Sex, men/women | 13/15 | ||
| Ethnicity: caucasic (%) | 28 (100) | ||
| Cardioaspirin (%) | 11 (39.3) | 11 (39.3) | 11 (39.3) |
| Hypoglycemic agents | |||
| Sulfonylureas (%) | 16 (57.1) | 16 (57.1) | 16 (57.1) |
| Metformin (%) | 19 (67.9) | 19 (67.9) | 19 (67.9) |
| Pioglitazone (%) | 4 (14.3) | 4 (14.3) | 4 (14.3) |
| Repaglinide (%) | 2 (7.1) | 2 (7.1) | 2 (7.1) |
| Alpha glucosidase inhibitor (%) | 1 (3.6) | 1 (3.6) | 1 (3.6) |
| Antihypertensive therapy | |||
| β-Blockers (%) | 5 (17.9) | 5 (17.9) | 5 (17.9) |
| ACE inhibitors (%) | 9 (32.1) | 9 (32.1) | 9 (32.1) |
| Sartanics (%) | 8 (28.6) | 8 (28.6) | 8 (28.6) |
| Calcium antagonists (%) | 5 (17.86) | 5 (17.86) | 5 (17.86) |
| Diuretics (%) | 3 (10.71) | 3 (10.71) | 3 (10.71) |
| Hypertension (%) | 17 (60.71) |
Data are presented as means ± standard deviation or absolute numbers and percentages.
Abbreviation: ACE, angiotensin-converting enzyme.